Biocept, Clarient Partner to Commercialize CTC Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare's Clarient will commercialize Biocept's blood test for circulating tumor cells under a deal announced today.

Clarient will market and sell the OncoCEE-BR test to community hospitals, pathologists, and medical oncologists. Biocept will run the test in its CLIA laboratory and Clarient Pathology Services will analyze the results.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.